Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma.
about
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaTruncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphomaFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentColocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity.Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment GroupSafety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas.Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study.A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma.Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumorsInhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomasMaintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumorsResponses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphomaStage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma.Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraTargeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent mannerThe mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedsideMammalian target of rapamycin inhibitor RAD001 sensitizes endometrial cancer cells to paclitaxel-induced apoptosis via the induction of autophagy.mTOR Inhibitors in Tuberous Sclerosis Complex.Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.Association of AMP-activated protein kinase with risk and progression of non-Hodgkin lymphoma.The role of bortezomib in the treatment of lymphoma.Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas.Novel acyl sulfonamide LY573636-sodium: effect on hematopoietic malignant cells.Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignanciesA phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies.Temsirolimus for the treatment of mantle cell lymphoma.
P2860
Q24607479-7EED22AB-498F-44D4-AB3A-82622A4867F0Q24655119-4E302E45-ECBF-4FA5-ABD9-4C6782BFCE7BQ28533949-30A84DE4-9527-41D8-A288-B989EB7B91FEQ30583249-EAD31935-F3B6-45D7-A85F-E7C6D75AB2E5Q33345588-AB7FA622-C9A3-4EAB-9ABE-EA13F97D5C4BQ33379949-1F666367-1930-4232-9387-A92140C2FF1BQ33382682-3428CA09-B2A7-4170-8AFE-63A734409D14Q33409982-452C312A-62A5-4121-8F7C-83F10D0C470BQ33413598-F98857BB-4726-4DEC-8796-4840C811E314Q33442575-27B7A2DA-13CB-4DF1-9077-33F80CA7881DQ33443555-3D1C2E7B-0129-49D5-9EC0-910D4504C959Q33566872-B2CF1634-5F4E-4954-881E-2736BCB64CCEQ33574190-14F9351E-08FE-4922-9B65-1EF484D7F618Q33685903-DFE4AD36-A727-4428-BFF4-D8A5879A4AC9Q33763742-0ECCA0F8-D53D-403E-8F29-7D1C63F65D23Q34091061-8E876AF0-7C5C-478A-B939-807AD15745A9Q34129360-25000D0D-22BD-43BA-B436-A90851C31FA8Q34255861-F5347B66-6A4D-4D14-BF2E-973FE15B482EQ34414736-A8B473CD-9C4C-4235-90EE-85269276721DQ34541728-4901E0A7-D12E-45CA-B300-E09762CBA651Q34568868-BE791949-7B18-4E69-8288-811994E00B80Q34632966-F1E950B2-3889-43C0-A463-3F90FB7D3A7BQ34965132-413D7489-A92C-4369-BA06-AF4A3A756633Q35779961-D131F8AB-0B14-445D-BAD3-BD1916D26519Q35859219-C80B4573-7C20-422F-8236-07D5651CEA84Q35989980-AC940D4B-510B-4051-825E-11F9D25C6687Q36254815-959179C1-AD0B-497B-BBEE-436201018C02Q36460639-992CAE8B-5AEB-4C3F-A1C0-241E7950CDB1Q36544778-F57C7AE1-93B0-4910-ADA6-EBCDD746BCABQ36742629-2B31B0B1-3FDB-4244-9396-BD8BD60758B8Q36780387-20F65B9E-6E1E-411E-8A9F-FB90198B7122Q37024073-29C85C4A-E6E0-4125-9B4F-7BA45CCA8F5BQ37028215-3CD3377A-1BD2-402F-B71A-FFCBA0230E92Q37074284-5DFFFE18-D6F2-4A05-9529-A3B6D2528E1FQ37137054-A7AD6D61-FECB-47F7-B05F-37577A91480DQ37432231-7855E27F-5C5C-4EE0-B44D-F2B20709ACF5Q37483253-4417600C-A0D9-4B27-949D-BC017767F17EQ37598141-B75E65CD-39A1-44FF-99BE-15DE5CD9DCD7Q37779489-D412A56F-89C9-4B9D-9482-83FC4FB4EF14Q37810084-84B8A271-D675-4648-95A9-95DDEBA4D09B
P2860
Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Antiproliferative activity of ...... gents in mantle cell lymphoma.
@en
type
label
Antiproliferative activity of ...... gents in mantle cell lymphoma.
@en
prefLabel
Antiproliferative activity of ...... gents in mantle cell lymphoma.
@en
P2093
P2860
P356
P1433
P1476
Antiproliferative activity of ...... gents in mantle cell lymphoma.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404471
P577
2006-11-30T00:00:00Z
P5875
P6179
1037850468